An Overview of FGF19 and FGF21: The Therapeutic Role in the Treatment of the Metabolic Disorders and Obesity

(2018) An Overview of FGF19 and FGF21: The Therapeutic Role in the Treatment of the Metabolic Disorders and Obesity. Hormone and Metabolic Research. pp. 441-452. ISSN 0018-5043

Full text not available from this repository.

Official URL: WOS:000434670100002

Abstract

Fibroblast growth factors (FGFs) are responsible for the regulation of a wide range of biological functions, among which cellular proliferation, survival, migration, and differentiation could be pointed out. FGF19 controls the enterohepatic bile acid/cholesterol system, and FGF21 modulates fatty acid/glucose metabolism. Obesity, type 2 diabetes, coronary artery disease, and cancer, all can alter FGF21 circulating concentrations. In contrast to FGF21, metabolic diseases exhibit reduced serum FGF19 levels. Accordingly, FGF19 and FGF21 play important roles in regulating glucose and lipid metabolism. Hence, we present here a timely review on the relationship between FGF19/21 and metabolic diseases, especially obesity, and their probable role in development and treatment of obesity seems necessary.

Item Type: Article
Keywords: fgf21 fgf19 metabolic disorders obesity fibroblast-growth-factor increases energy-expenditure improves insulin sensitivity activated-receptor-gamma hepatic lipid-metabolism bile-acid biosynthesis brown adipose-tissue weight-loss ppar-alpha serum concentrations
Subjects: WH Hemic and Lymphatic Systems > WH 600-700 Lymphatic System
Divisions: Faculty of Medicine > Departments of Clinical Sciences > Department of Neurology
Food Security Research Center
Page Range: pp. 441-452
Journal or Publication Title: Hormone and Metabolic Research
Journal Index: ISI
Volume: 50
Number: 6
Identification Number: https://doi.org/10.1055/a-0623-2909
ISSN: 0018-5043
Depositing User: Zahra Otroj
URI: http://eprints.mui.ac.ir/id/eprint/6489

Actions (login required)

View Item View Item